ESPE Abstracts

Introduction: Lipid disorders are a common complication of anticancer therapy. These disorders may be included in both the metabolic syndrome or also may be associated with increased risk of cardiovascular disease. The aim of our study is to evaluate lipid profile in children after anticancer treatment.

Materials and methods: Study group consisted of 44 patients (aged 3.25–16 years) with solid tumors, at least one year after cessation of anticancer treatment. Group was compared with a control group (31 healthy children). Following parameters were evaluated: cholesterol SDS, triglycerides SDS, LDL-C SDS, HDL-C SDS, weight SDS, height SDS, BMI SDS. Statistical distances (τ-risk factors of dyslipidemia, τ=([(Ei−Oi)2]×100)/Ei, wherein E_i =median of the control group; O_i = median in the study group) for lipids parameters between study group and the control group were calculated. Indicators of susceptibility to atherosclerosis were calculated.

Results: Following abnormal lipid parameters were found: hypercholesterolemia in 45.46% elevated TG SDS in 25%, elevated LDL-C SDS in 20.45%, low HDL-C in 6.82% of cases. Patient in study group were at higher risk of lipid disorders (sum of τ=150.98) for cholesterol SDS (τ=180.3), LDL-C SDS (τ=8.82) and TG SDS (τ=10.03) than in control group. In children with cancer was observed lower risk of reduced HDL-C SDS (τ=−48.17), compared to healthy children. Elevated values of susceptibility to atherosclerosis were found: for index Castelli in 11.36%, for ratio cholesterol C/HDL-C in 11.36%, for ratio LDL-C/HDL-C in 29.55% of children with cancer. Overweight or obesity were found in 30.24% of children with cancer.

Conclusions: Children after anticancer treatment are exposed to disorders of lipid metabolism. The role of these disorders and their impact on health in adult life requires further study and long-term follow-up.